Liane Rae Teplitsky Purchases 1,001 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky bought 1,001 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were bought at an average price of $49.95 per share, with a total value of $49,999.95. Following the completion of the acquisition, the chief operating officer directly owned 4,095 shares in the company, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Liane Rae Teplitsky also recently made the following trade(s):

• On Monday, August 31st, Liane Rae Teplitsky acquired 1,024 shares of Pulse Biosciences stock. The shares were bought at an average cost of $48.80 per share, with a total value of $49,971.20.
• On Friday, August 28th, Liane Rae Teplitsky bought 1,034 shares of Pulse Biosciences stock. The stock was purchased at an average cost of $48.35 per share, for a total transaction of $49,993.90.
• On Wednesday, August 26th, Liane Rae Teplitsky purchased 1,036 shares of Pulse Biosciences stock. The shares were purchased at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Price Performance

Pulse Biosciences stock traded up $0.59 during trading hours on Wednesday, reaching $52.68. The stock had a trading volume of 977,767 shares, compared to its average volume of 461,050. The company has a fifty day simple moving average of $36.93 and a 200-day simple moving average of $27.60. Pulse Biosciences, Inc has a 52 week low of $12.56 and a 52 week high of $54.39. The stock has a market cap of $3.65 billion, a PE ratio of -44.64 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Research analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Pulse Biosciences in the first quarter worth about $323,000. Creative Planning lifted its holdings in shares of Pulse Biosciences by 26.3% during the second quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after purchasing an additional 3,951 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock worth $338,000 after purchasing an additional 8,197 shares in the last quarter. Norges Bank purchased a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $302,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $158,000. Institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price for the company. Canaccord Genuity Group lifted their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, Mizuho set a $45.00 target price on Pulse Biosciences in a research report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.